LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

34.56 -0.6

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.42

Massimo

35.19

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+49.76% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	666M 6.3B
Apertura precedente	35.16
Chiusura precedente	34.56

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 mag 2026, 23:55 UTC

Utili

Review & Preview: Still Going Strong -- Barrons.com

8 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 20:49 UTC

Utili

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mag 2026, 20:25 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Net $115M

8 mag 2026, 19:20 UTC

Discorsi di Mercato

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mag 2026, 19:18 UTC

Utili

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mag 2026, 19:16 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:08 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:05 UTC

Utili

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mag 2026, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mag 2026, 18:51 UTC

Utili

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mag 2026, 18:49 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 18:41 UTC

Utili

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mag 2026, 17:14 UTC

Utili

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mag 2026, 17:04 UTC

Discorsi di Mercato

Zcash Caps Off Parabolic Week -- Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 mag 2026, 15:36 UTC

Discorsi di Mercato

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 mag 2026, 15:20 UTC

Discorsi di Mercato

'Altcoin Season' Indicator on the Rise -- Market Talk

8 mag 2026, 15:20 UTC

Discorsi di Mercato

Utili

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 mag 2026, 15:05 UTC

Discorsi di Mercato

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 mag 2026, 14:42 UTC

Discorsi di Mercato

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 mag 2026, 14:39 UTC

Discorsi di Mercato

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

49.76% in crescita

Previsioni per 12 mesi

Media 52.1 USD 49.76%

Alto 64 USD

Basso 35 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.